Results 11 to 20 of about 5,314 (201)

Structure-activity relationships of fluorene compounds inhibiting HCV variants [PDF]

, 2020
Approximately 71 million people suffer from hepatitis C virus (HCV) infection worldwide. Persistent HCV infection causes liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, resulting in approximately 400,000 deaths ...
Gadhe, Changdev G., JANG, SUNG KEY, Keum, Gyochang, Kim, Byeong Moon, Kim, Hee Sun, Kohara, Michinori, Lee, Jae Seung, Moon, Heejo, Mun, Jaegon, Pae, Ae Nim, You, Youngsu   +10 more
core   +1 more source

In-Vitro and In-Vivo Evaluation of Velpatasvir- Loaded Mesoporous Silica Scaffolds. A Prospective Carrier for Drug Bioavailability Enhancement

Pharmaceutics, 2020
The limited aqueous solubility of many active pharmaceutical ingredients (APIs) is responsible for their poor performance and low drug levels in blood and at target sites. Various approaches have been adopted to tackle this issue.
Yasir Mehmood, Ikram Ullah Khan, Yasser Shahzad, Rizwan Ullah Khan, Muhammad Shahid Iqbal, Haseeb Ahmad Khan, Ikrima Khalid, Abid Mehmood Yousaf, Syed Haroon Khalid, Sajid Asghar, Muhammad Asif, Talib Hussain, Shefaat Ullah Shah   +12 more
doaj   +1 more source

DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.

Journal of Education, Health and Sport, 2023
Introduction Cirrhosis is a condition in which the liver becomes fibrotic following damage to the liver and transforms the architecture of the organ into regenerative nodules.
Kamila Abram, Patryk Banaś, Justyna Adamus, Jakub Rafał Pierzchała, Katarzyna Bednarz, Natalia Sobańska, Aleksandra Paulina Banasiak, Rafał Teichman, Jakub Kasprowicz, Michał Hyjek   +9 more
doaj   +1 more source

Molecular docking analysis of peptide-based antiviral agents against SARS-CoV-2 main protease: an approach towards drug repurposing

Exploration of Medicine, 2023
Aim: Utilizing the therapeutic potentials of previously approved medications against a new target or pharmacological response is known as drug repurposing.
Abhishek Chaurasiya, Abhimannu Shome, Pooja A. Chawla   +2 more
doaj   +1 more source

Real-World Impact of a Simplified 'Test and Treat' Strategy for In-Hospital HCV Micro-Elimination. [PDF]

J Viral Hepat
ABSTRACT Hepatitis C virus (HCV) micro‐elimination faces challenges from fragmented care pathways, particularly in high‐prevalence regions with complex genotypes and socioeconomic barriers. This study evaluated a simplified ‘Test and Treat’ (TNT) strategy to enhance in‐hospital HCV micro‐elimination by reducing delays and improving linkage to care ...
You C, Diao Y, Tang J, Tang J, Deng W, Zheng C, Liao D, Song D, Wang J, Pu Y.   +9 more
europepmc   +2 more sources

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan

Frontiers in Pharmacology, 2020
BackgroundDirect-acting antivirals (DAAs) therapeutic regimens are highly effective against chronic hepatitis C virus (HCV) infection. However, HCV patients with genotype 3 (GT3) respond in a suboptimal way.
Saima Mushtaq, Tayyab Saeed Akhter, Amjad Khan, Aamir Sohail, Arshad Khan, Sobia Manzoor   +5 more
doaj   +1 more source

Prevalence of Hepatitis C Virus Infection and Efficacy of Sofosbuvir–Velpatasvir and Sofosbuvir–Daclatasvir Treatment Regimens in End-stage Renal Disease Patients on Maintenance Hemodialysis

Saudi Journal of Kidney Diseases and Transplantation, 2023
Patients with end-stage renal disease (ESRD) are at an increased risk of hepatitis C virus (HCV) infection. This study evaluated the prevalence of HCV infection in patients with ESRD on maintenance hemodialysis (MHD) and studied the effectiveness of ...
Mohammad Ashraf Bhat, Aadil Nabi Mir, Manzoor Ahmad Parry, Irshad Ahmad Parray   +3 more
doaj   +1 more source

VIROLOGICAL RESPONSES OF VELPATASVIR/SOFOSBUVIR IN PATIENTS WITH HCV GENOTYPE 3

Journal of University Medical & Dental College, 2020
BACKGROUND & OBJECTIVE: The role of Velpatasvir/Sofosbuvir in the treatment of hepatitis C virus type 3 infection is evaluated in terms of virologic responses. i.e Rapid Virological Response (RVR) End of treatment response (ETR) and Sustained virological
Muhammad Sarfraz, Arshad Rabbani
doaj   +1 more source

Real‐world impact of a subsidy decision of sofosbuvir–velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes

JGH Open, 2023
Background and Aim Sofosbuvir–velpatasvir was recommended for subsidy to treat chronic hepatitis C in Singapore in 2018. We measured the impact of the subsidy decision on clinical practice and patient outcomes.
Chee‐Kiat Tan, Xue‐Shi Luo, Benjamin Shao‐Kiat Ong, Liang Lin, Kwong‐Hoe Ng   +4 more
doaj   +1 more source

Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. [PDF]

, 2016
There have been dramatic advancements in the treatment of chronic hepatitis C (HCV) infection. This is largely due to the approval of several direct-acting antiviral agents (DAAs) from a variety of medication classes with novel mechanisms of action ...
Bidell, Monique R, Faragon, John, McLaughlin, Milena, Morse, Caroline, Patel, Nimish   +4 more
core   +2 more sources